Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Change in Accured Expenses (2022 - 2025)

Coya Therapeutics' Change in Accured Expenses history spans 4 years, with the latest figure at -$1.2 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 395.58% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached $229472.0, down 3.0%, while the annual FY2024 figure was -$1.5 million, 270.66% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$1.2 million at Coya Therapeutics, down from $1.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.7 million in Q4 2023 and bottomed at -$1.3 million in Q1 2023.
  • The 4-year median for Change in Accured Expenses is $166153.0 (2022), against an average of $30460.0.
  • The largest YoY upside for Change in Accured Expenses was 1567.72% in 2023 against a maximum downside of 875.4% in 2023.
  • A 4-year view of Change in Accured Expenses shows it stood at $102751.0 in 2022, then skyrocketed by 1567.72% to $1.7 million in 2023, then crashed by 101.24% to -$21174.0 in 2024, then plummeted by 5567.23% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Change in Accured Expenses are -$1.2 million (Q3 2025), $1.0 million (Q2 2025), and $421523.0 (Q1 2025).